Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AMLX 
Amylyx Pharmaceuticals Inc (AMLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: AMLX (4-star) is a STRONG-BUY. BUY since 60 days. Simulated Profits (99.22%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14.88
1 Year Target Price $14.88
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.08% | Avg. Invested days 59 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.28B USD | Price to earnings Ratio - | 1Y Target Price 14.88 |
Price to earnings Ratio - | 1Y Target Price 14.88 | ||
Volume (30-day avg) 7 | Beta -0.44 | 52 Weeks Range 2.60 - 13.10 | Updated Date 09/17/2025 |
52 Weeks Range 2.60 - 13.10 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) 79106.43% |
Management Effectiveness
Return on Assets (TTM) -46.74% | Return on Equity (TTM) -87.42% |
Valuation
Trailing PE - | Forward PE 2.77 | Enterprise Value 1100878486 | Price to Sales(TTM) 4.44 |
Enterprise Value 1100878486 | Price to Sales(TTM) 4.44 | ||
Enterprise Value to Revenue 6446.63 | Enterprise Value to EBITDA -11.71 | Shares Outstanding 106667000 | Shares Floating 58612428 |
Shares Outstanding 106667000 | Shares Floating 58612428 | ||
Percent Insiders 7.95 | Percent Institutions 79.15 |
Upturn AI SWOT
Amylyx Pharmaceuticals Inc
Company Overview
History and Background
Amylyx Pharmaceuticals was founded in 2013 by Joshua Cohen and Justin Klee. They developed AMX0035, a drug intended to treat neurodegenerative diseases. The company went public on the Nasdaq in January 2022.
Core Business Areas
- Neurology Therapeutics: Focuses on the development and commercialization of novel therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS).
Leadership and Structure
Joshua Cohen and Justin Klee are the Co-CEOs. The company has a board of directors and a typical organizational structure for a biotechnology company, with departments for research and development, clinical trials, commercialization, and finance.
Top Products and Market Share
Key Offerings
- Relyvrio/Albrioza (AMX0035): Relyvrio is a combination of sodium phenylbutyrate and taurursodiol approved for the treatment of ALS. The market share is still developing post-approval. Competitors include Radicava (edaravone) by Mitsubishi Tanabe Pharma and riluzole, a generic drug.
Market Dynamics
Industry Overview
The biotechnology industry, particularly in neurology, is characterized by high risk, high reward. There is a significant unmet need for effective treatments for neurodegenerative diseases.
Positioning
Amylyx is positioned as an innovator in the ALS treatment space with Relyvrio. Its competitive advantage lies in the novel formulation of its drug and the clinical trial data supporting its efficacy, although the approval pathway and efficacy have been debated.
Total Addressable Market (TAM)
The global ALS treatment market is estimated to reach billions of USD. Amylyx is positioned to capture a significant portion of this TAM with Relyvrio, but its success depends on continued positive clinical data and market acceptance.
Upturn SWOT Analysis
Strengths
- FDA and Health Canada Approval for Relyvrio/Albrioza
- Novel drug formulation
- Strong intellectual property protection
- Dedicated leadership team
Weaknesses
- Limited product portfolio (primarily Relyvrio)
- Reliance on a single indication (ALS)
- Potential for negative clinical trial results in ongoing studies
- High cash burn rate typical of biotech companies
Opportunities
- Expansion into other neurodegenerative diseases
- Partnerships with larger pharmaceutical companies
- Geographic expansion to other markets
- Development of new formulations or delivery methods
Threats
- Competition from existing and emerging ALS treatments
- Regulatory challenges and potential for withdrawal of approval
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- MTPC (Mitsubishi Tanabe Pharma Corporation)
- BIIB (Biogen Inc.)
- ABBV (AbbVie Inc)
Competitive Landscape
Amylyx faces competition from established players in the neurology space. Its advantage lies in its novel drug, but it needs to demonstrate long-term efficacy and cost-effectiveness.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by the commercial launch of Relyvrio/Albrioza. Early sales data is critical for understanding trajectory.
Future Projections: Future growth depends on market penetration of Relyvrio/Albrioza, expansion into new markets, and potential pipeline development.
Recent Initiatives: Focus on commercialization of Relyvrio/Albrioza, ongoing clinical trials, and exploring potential pipeline candidates.
Summary
Amylyx is a relatively new player in the ALS treatment market with a recently approved drug, Relyvrio. The company's success hinges on the drug's long-term efficacy, market penetration, and expansion into new areas. The company needs to manage cash flow carefully and navigate a competitive landscape with established pharmaceutical giants. Further clinical data and sales performance will be crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News Sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amylyx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-01-07 | Co-Founder, Co-CEO & Director Mr. Joshua B. Cohen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://amylyx.com |
Full time employees 123 | Website https://amylyx.com | ||
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.